ArticleVaccine2011
Α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model.
Article in Vaccine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 48 citations in OpenAlex.
- Extracellular Vesicles ofJournal of extracellular biology · 2026Article
- Review
- Mucosal vaccination in a murine gnotobiotic model ofInfection and immunity · 2024Article
- A core UPS molecular complement implicates unique endocytic compartments at the parasite-host interface inVirulence · 2023Article
- The NLRP3 inflammasome recognizes alpha-2 and alpha-7.3 giardins and decreases the pathogenicity of Giardia duodenalis in mice.Parasites & vectors · 2023Article
- Review
- Protozoa-Derived Extracellular Vesicles on Intercellular Communication with Special Emphasis onMicroorganisms · 2022Review
- Conjugated linoleic acid modifies transcriptional cytokine profile and induces early specific secretory IgA response inIranian journal of basic medical sciences · 2022Article
- Codelivery of Antigens and Adjuvant in Polymeric Nanoparticles Coated With Native Parasite Membranes Induces Protective Mucosal Immunity Against Giardia lamblia.The Journal of infectious diseases · 2022Article
- Conserved metabolic enzymes as vaccine antigens for giardiasis.PLoS neglected tropical diseases · 2022Article
- Disease Biomarkers of Giardiasis.Journal of parasitology research · 2022Review
- "Immunoinformatic Identification of T-Cell and B-Cell Epitopes FromFrontiers in cellular and infection microbiology · 2021Article
- Giardia duodenalis Virulence - "To Be, or Not To Be".Current tropical medicine reports · 2021Review
- The Delay in the Licensing of Protozoal Vaccines: A Comparative History.Frontiers in immunology · 2020Review
- The enigmatic role of fungal annexins: the case of Cryptococcus neoformans.Microbiology (Reading, England) · 2019Article
- Identification of Conserved Candidate Vaccine Antigens in the Surface Proteome of Giardia lamblia.Infection and immunity · 2019Article
- Genetic variation in potential Giardia vaccine candidates cyst wall protein 2 and α1-giardin.Parasitology research · 2017Article
- Prokaryotic Expression ofBioMed research international · 2017Article
- Oral Vaccination with Attenuated Salmonella typhimurium-Delivered TsPmy DNA Vaccine Elicits Protective Immunity against Trichinella spiralis in BALB/c Mice.PLoS neglected tropical diseases · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Giardia lamblia is a leading protozoan cause of diarrheal disease worldwide, yet preventive medical strategies are not available. A crude veterinary vaccine has been licensed for cats and dogs, but no defined human vaccine is available. We tested the vaccine potential of three conserved antigens previously identified in human and murine giardiasis, α1-giardin, α-enolase, and ornithine carbamoyl transferase, in a murine model of G. lamblia infection. Live recombinant attenuated Salmonella enterica Serovar Typhimurium vaccine strains were constructed that stably expressed each antigen, maintained colonization capacity, and sustained total attenuation in the host. Oral administration of the vaccine strains induced antigen-specific serum IgG, particularly IgG(2A), and mucosal IgA for α1-giardin and α-enolase, but not for ornithine carbamoyl transferase. Immunization with the α1-giardin vaccine induced significant protection against subsequent G. lamblia challenge, which was further enhanced by boosting with cholera toxin or sublingual α1-giardin administration. The α-enolase vaccine afforded no protection. Analysis of α1-giardin from divergent assemblage A and B isolates of G. lamblia revealed >97% amino acid sequence conservation and immunological cross-reactivity, further supporting the potential utility of this antigen in vaccine development. Together. These results indicate that α1-giardin is a suitable candidate antigen for a vaccine against giardiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.